Syngene Acquires its First Manufacturing Facility in US
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services.
Syngene | 11/03/2025 | By Aishwarya
Syngene to acquire multi-modal facility from Stelis Biopharma Ltd
Syngene to acquire multi-modal facility from Stelis Biopharma Ltd, adding 20,000 liters of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high speed, commercial scale, fill-finish unit
Syngene | 06/07/2023 | By Sudeep Soparkar | 390
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy